HC Wainwright & Co. Reiterates Buy on Catalyst Pharmaceuticals, Maintains $24 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on Catalyst Pharmaceuticals (NASDAQ:CPRX) and maintained a price target of $24.
August 11, 2023 | 11:59 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Catalyst Pharmaceuticals has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $24.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates their continued confidence in Catalyst Pharmaceuticals. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100